Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNA Avidity Biosciences, Inc.

Market Closed 12-12 16:00:00 EST

71.83

+0.23

+0.32%

盘后71.89

+0.06+0.08%

17:56 EST

High71.88	Low71.52	Vol1.98M
Open71.59	D1 Closing71.60	Amplitude0.50%
Mkt Cap10.82B	Tradable Cap8.12B	Total Shares150.68M
T/O142.00M	T/O Rate1.75%	Tradable Shares113.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Avidity Biosciences, Inc.","latestPrice":71.83,"timestamp":1765573200000,"preClose":71.6,"halted":0,"volume":1978459,"hourTrading":{"tag":"盘后","latestPrice":71.89,"preClose":71.83,"latestTime":"17:56 EST","volume":761613,"amount":54706707.79,"timestamp":1765580176874},"delay":0,"floatShares":112999999,"shares":150675742,"eps":-4.185146,"marketStatus":"Market Closed","change":0.23,"latestTime":"12-12 16:00:00 EST","open":71.59,"high":71.88,"low":71.52,"amount":141995723.68933,"amplitude":0.005028,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.185146,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":71.6,"preHourTrading":{"tag":"盘前","latestPrice":71.59,"preClose":71.6,"latestTime":"09:29 EST","volume":41,"amount":2935.19,"timestamp":1765549799914},"postHourTrading":{"tag":"盘后","latestPrice":71.89,"preClose":71.83,"latestTime":"17:56 EST","volume":761613,"amount":54706707.79,"timestamp":1765580176874},"volumeRatio":0.7487016181183703,"impliedVol":0.3236,"impliedVolPercentile":0.132},"requestUrl":"/m/hq/s/RNA/wiki","defaultTab":"wiki","newsList":[{"id":"2590534392","title":"Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534392","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534392?lang=en_us&edition=fundamental","pubTime":"2025-12-11 01:37","pubTimestamp":1765388276,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009354923.USD","BK4588","BK4139","BK4127","BK4505","BK4585","OPY","RNA","DYN"],"gpt_icon":0},{"id":"2589388148","title":"Assessing Avidity Biosciences (RNA) Valuation After Its Strong Multi‑Year Share Price Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2589388148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589388148?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:13","pubTimestamp":1765160037,"startTime":"0","endTime":"0","summary":"Avidity Biosciences (RNA) has quietly turned into a strong performer, with the stock up sharply this year as investors warm to its RNA therapeutic platform and advancing muscular dystrophy pipeline.\nSee our latest analysis for Avidity Biosciences.\nThat surge in optimism is showing up in the numbers, with a roughly 49 percent 3 month share price return feeding into a powerful 129 percent year to date share price gain and an eye catching 3 year total shareholder return above 550 percent. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rna/avidity-biosciences/news/assessing-avidity-biosciences-rna-valuation-after-its-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rna/avidity-biosciences/news/assessing-avidity-biosciences-rna-valuation-after-its-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0009354923.USD","RNA","DCF","BK4585","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"2588550720","title":"ProQR to Participate in 8th Annual Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588550720","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588550720?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec.  01, 2025  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196934/33039/en/ProQR-to-Participate-in-8th-Annual-Evercore-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","LU2041044095.USD","LU0029874061.USD","LU2413666426.HKD","IE00BN0W2V16.EUR","BK4106","A","LU1721428933.USD","LU2413666699.HKD","BK4585","LU0702159343.USD","LU1165135440.EUR","LU0128526141.USD","BK4505","BK4121","BK4139","G","LU0702159699.USD","LU2092937221.SGD","IE00BN0W2W23.USD","LU1166156734.SGD","BK4588","IE0009354923.USD","LU0347712357.USD","LU2089279066.USD","BK4523","XLV","IE00BN0W2T93.GBP","LU2229751404.USD","BK4567","LU1543694498.USD","BK4137","XBI","HCSG","RNA","BK4226"],"gpt_icon":0},{"id":"2586299978","title":"Will FDA Accelerated Pathway for Delpacibart Zotadirsen Reshape Avidity Biosciences' (RNA) Rare Disease Trajectory?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299978?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:27","pubTimestamp":1764199665,"startTime":"0","endTime":"0","summary":"In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway.\nThis move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators.\nWe'll explore how securing FDA...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rna/avidity-biosciences/news/will-fda-accelerated-pathway-for-delpacibart-zotadirsen-resh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rna/avidity-biosciences/news/will-fda-accelerated-pathway-for-delpacibart-zotadirsen-resh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","IE0009354923.USD","BK4505","RNA","BK4139"],"gpt_icon":0},{"id":"2586471816","title":"BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471816?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:33","pubTimestamp":1764081229,"startTime":"0","endTime":"0","summary":"BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug**Shares of drug developer Sarepta Therapeutics SRPT.O 2.1% to $19.78 in early trading ** Co says U.S. FDA has approved the start of new study to test whether adding an extra immune-suppressing drug can make its gene therapy for Duchenne muscular dystrophy safer for patients who can no longer walk** DMD is a rare genetic disorder that causes progressive muscle weakness and loss, mostly in boys and young men** The early stage trial enrolls ~25 patients who can no longer walk, co says** Patients will receive co's Elevidys gene therapy plus sirolimus to lower risk of serious liver complications - RNA** The therapy is approved for children aged four and older who can walk, but not for those unable to walk due to safety concerns - RNA** Including session's move, stock down ~85% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","RNA","SRPT","IE00BFTCPJ56.SGD","IE0009354923.USD","BK4139","IE0002141913.USD","BK4588","BK4585","BK4505","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2586471301","title":"Silexion Therapeutics completes toxicology studies for SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471301?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:20","pubTimestamp":1764080440,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the successful completion of toxicology studies for SIL204, the Company’s next-generation RNA silencing ther...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4139","BK4505","SLXN","BK4539","LENZ","RNA","BK4588","IE0009354923.USD"],"gpt_icon":0},{"id":"2586479668","title":"Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479668","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479668?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:15","pubTimestamp":1764080100,"startTime":"0","endTime":"0","summary":"Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194426/0/en/Silexion-Therapeutics-Successfully-Completes-Toxicology-Studies-for-SIL204-Next-Generation-RNA-Silencing-Therapy-Ahead-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","RNA","SLXN","IE0009354923.USD","BK4585","BK4588","BK4007","BK4539","BK4505"],"gpt_icon":0},{"id":"2586413340","title":"Avidity Biosciences Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586413340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586413340?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:10","pubTimestamp":1764022247,"startTime":"0","endTime":"0","summary":"Avidity Biosciences, Inc. has announced that it will hold a special meeting of stockholders. During the meeting, stockholders will vote on the adoption of the Agreement and Plan of Merger, dated as of October 25, 2025, among Novartis AG and other involved parties, as well as additional related proposals. The meeting will also address any other matters that may properly come before the meeting or any adjournment or postponement thereof.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8kW6Qp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IE0009354923.USD","RNA","BK4505","BK4585"],"gpt_icon":0},{"id":"2585462375","title":"Sarepta provides update on SRP-1003 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462375","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462375?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:50","pubTimestamp":1763988635,"startTime":"0","endTime":"0","summary":"Sarepta (SRPT) shared progress in the Phase 1/2 multiple ascending dose clinical study of SRP-1003, an investigational small interfering RNA therap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sarepta-provides-update-on-srp-1003-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sarepta-provides-update-on-srp-1003-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","SRPT","BK4139","IE0009355771.USD","RNA","BK4505","BK4588","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE0002141913.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"1170604201","title":"CSPC PHARMA (01093): Dual-Chain Small Interfering RNA Drug (SYH2061 Injection) Receives US Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170604201","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170604201?lang=en_us&edition=fundamental","pubTime":"2025-11-24 18:26","pubTimestamp":1763979976,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that its self-developed Class 1 chemical new drug, the dual-chain small interfering RNA drug (SYH2061 Injection), has received approval from the U.S. Food and Drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LU1993786604.SGD","01093","LU0880133367.SGD","LU0067412154.USD","HK0000165453.HKD","BK1191","BK4585","IE00B5MMRT66.SGD","LU1152091168.USD","IE0008368742.USD","RNA","IE00B543WZ88.USD","LU0140636845.USD","LU0072913022.USD","LU1008478684.HKD","IE00BZ08YS42.EUR","BK4505","SG9999004220.SGD","LU1807302812.USD","BK1521","BK1515","IE00B031HY20.USD","LU1226288253.USD","LU1813983027.USD","LU1226287529.USD","LU1960683339.HKD","LU1152091754.HKD","LU2039709279.SGD","LU1226287875.USD","LU0326950275.SGD","LU0315179316.USD","LU0501845795.SGD","IE0008369823.USD","LU0314109678.HKD","LU1226288170.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1951186391.HKD","BK4139","BK4588","LU1328277881.USD","LU1226287792.SGD"],"gpt_icon":0},{"id":"1128334973","title":"HK Stock Movement | MIRXES-B (02629) Rises Nearly 8% in Early Trading, Partners with Walvax to Expand ASEAN Market and Build RNA Precision Medicine Innovation System","url":"https://stock-news.laohu8.com/highlight/detail?id=1128334973","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128334973?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:50","pubTimestamp":1763949022,"startTime":"0","endTime":"0","summary":"MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","BK4588","BK4585","02629","BK1161","IE0009354923.USD","BK4139"],"gpt_icon":0},{"id":"1105010595","title":"HK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1105010595","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105010595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:48","pubTimestamp":1763704100,"startTime":"0","endTime":"0","summary":"MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million. The company announced it recently signed a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK0046","BK4139","BK4505","RNA","BK0077","02629","BK1161","BK0070","BK0239","BK4585","BK4588","300142"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU1037948897.HKD","QID",".IXIC","SG9999014559.SGD","IE00BN8TJ469.HKD","LU1057294990.SGD","MRK","NVIW.SI","LU2089984988.USD","LU0098860793.USD","CELC","VIGL","REPL","BK4532","PSQ","LU0861579265.USD","QLD","LU2023250504.SGD","NVS","NQmain","IE00BSNM7G36.USD","QURE","SGXZ57979304.SGD","LU0238689110.USD","SQQQ","CSL.AU","LU0289739699.SGD","RNA","USAW.SI","LU2324357040.USD","USJW.SI","TSYW.SI","LU1934455194.USD","VRNA","BK4559","PFE","LU1934455277.USD","LU1929549753.HKD","TQQQ","LU0265550946.USD","LU1430594728.SGD","MNQmain","IE000M9KFDE8.USD","LU0985320562.USD","LU0265550359.USD","BK4505","LU1116320901.HKD","BK7067","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2585157530","title":"These 15 stocks are still showing momentum - and a market-beating edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157530","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157530?lang=en_us&edition=fundamental","pubTime":"2025-11-21 04:45","pubTimestamp":1763671500,"startTime":"0","endTime":"0","summary":"'Big mo' stock strategies have lost their advantage, but these companies display relative strength. When it comes to following momentum strategies in the stock market, all are based on the same basic premise: Stocks that have recently performed the best are likely to continue performing well for a while longer. The difference between the various strategies boils down to how to put that premise into practice.The answer that has academia's seal of approval is to define momentum over the period from 12 months previously to one month previously, and to reform the portfolio on a monthly basis.Over 150 years of U.S. stock-market history, this approach has handily beaten the market average. But over the past couple of decades, momentum strategies have weakened.The study's authors obtained data showing not only the web pages that a large sample of investors focused on before buying or selling stocks, but how long they spent on each of tho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","LU0444973449.USD","LU1235294995.USD","BK4585","LU0053671581.USD","BK4539","MP","LU0154236417.USD","GH","LU0823414478.USD","BK4141","LU1861220033.SGD","LU0477156953.USD","BK4139","BK4505","LU1989764664.SGD","LU0106261612.USD","INSM","LU0205193047.USD","SATS","WBD","LU0889565916.HKD","LU0154245673.USD","OKLO","WDC","RNA","LU0240878834.USD","LU1988902786.USD","W","BK4170","LU2290526834.HKD","BK4168","BK4108","LU2264538146.SGD","IE0009354923.USD","LU0205194284.USD","LU0505663152.USD","LU0006061336.USD","LU0823421416.USD","CRDO","LU0154245756.USD","LU2360107168.USD","LU0320765992.SGD","SNDK","LU0823414551.USD","BE","CIEN","IE00BD6J9T35.USD","BK4512","BK4524"],"gpt_icon":1},{"id":"2585518411","title":"Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2585518411","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585518411?lang=en_us&edition=fundamental","pubTime":"2025-11-21 01:43","pubTimestamp":1763660609,"startTime":"0","endTime":"0","summary":"Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48983890/novartis-projects-faster-growth-through-2030-after-raising-drug-forecasts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","RNA","BK4585","NVS","IE00BFTCPJ56.SGD","BK4007","BK4505","IE00B2B36J28.USD","BK4139","BK4532","LU0070302665.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4578","IE0002141913.USD","LU0211331839.USD","BK4588","IE00B4R5TH58.HKD","LU0208291251.USD","LU0320765489.SGD","IE0009354923.USD"],"gpt_icon":0},{"id":"2584180335","title":"Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180335","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584180335?lang=en_us&edition=fundamental","pubTime":"2025-11-20 18:17","pubTimestamp":1763633820,"startTime":"0","endTime":"0","summary":"Novartis said higher expectations for key drugs and recent dealmaking that replenished its medicine pipeline should keep sales growing into the 2030s as the drugmaker plows ahead with a U.S. push.The Swiss pharmaceutical company is confronting investor concerns about patent expirations for some of its topselling products, as it continues drug-pricing talks with the White House and moves forward with a $23 billion plan to bolster its U.S. footprint.\"We are very confident in the U.S. outlook,\" Novartis Chief Executive Vas Narasimhan said Thursday during a call with reporters.The company is aiming to produce locally all key drugs it sells in the U.S. It picked North Carolina as the site of a new manufacturing hub, adding facilities to expand its existing presence as part of a previously announced pledge to invest billions of dollars in its U.S.-based infrastructure over the next five years.The Avidity deal added to a series of smaller acquisitions and licensing agreements that allowed Nov","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU0320765489.SGD","BK4588","IE0002141913.USD","IE00B4R5TH58.HKD","BK4139","BK4578","LU0211331839.USD","LU0208291251.USD","NVS","BK4532","IE00BJT1NW94.SGD","IE0009354923.USD","IE00B2B36J28.USD","RNA","IE00BFTCPJ56.SGD","BK4007","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4585","LU0070302665.USD"],"gpt_icon":0},{"id":"2584900922","title":"Novartis sees sales boost from key cancer drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584900922","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584900922?lang=en_us&edition=fundamental","pubTime":"2025-11-20 14:37","pubTimestamp":1763620673,"startTime":"0","endTime":"0","summary":"UPDATE 3-Novartis sees sales boost from key cancer drugsRaises peak sales forecasts for cancer drugs Kisqali, ScemblixNovartis to keep a 'high bar' for future deals, CEO says Investors take cautious approach for growth beyond 2030 Adds details from media call throughout, analysts comments in paragraphs 7 and 9By Ludwig Burger and Bhanvi Satija","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nL1N3WW065:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","RNA","BK4139","BK4585","IE0009354923.USD"],"gpt_icon":0},{"id":"2584077129","title":"Novartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC","url":"https://stock-news.laohu8.com/highlight/detail?id=2584077129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584077129?lang=en_us&edition=fundamental","pubTime":"2025-11-20 14:16","pubTimestamp":1763619366,"startTime":"0","endTime":"0","summary":"Nov 20 (Reuters) - NOVARTIS AG ::*PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS*PEAK SALES GUIDANCE UPGRADED FOR KISQALI AND SCEMBLIX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nRSD4lCd25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4588","BK4139","BK4505","BK4585","RNA"],"gpt_icon":0},{"id":"2584421439","title":"BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44","url":"https://stock-news.laohu8.com/highlight/detail?id=2584421439","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584421439?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:15","pubTimestamp":1763561728,"startTime":"0","endTime":"0","summary":"BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44Avidity Biosciences Inc RNA.O:AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA9GRHQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","RNA","IE0009354923.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2584426049","title":"Avidity Biosciences Inc - Plans Bla Submission for Del-Zota in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584426049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584426049?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:13","pubTimestamp":1763561608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA9GRHQQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4505","BK4139","RNA","IE0009354923.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aviditybiosciences.com","stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0143},{"period":"3month","weight":0.6055},{"period":"6month","weight":1.2898},{"period":"1year","weight":1.1277},{"period":"ytd","weight":1.4701}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.029515},{"month":2,"riseRate":0.6,"avgChangeRate":0.100374},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.109934}],"exchange":"NASDAQ","name":"Avidity Biosciences, Inc.","nameEN":"Avidity Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avidity Biosciences, Inc.,RNA,Avidity Biosciences, Inc.股票,Avidity Biosciences, Inc.股票老虎,Avidity Biosciences, Inc.股票老虎国际,Avidity Biosciences, Inc.行情,Avidity Biosciences, Inc.股票行情,Avidity Biosciences, Inc.股价,Avidity Biosciences, Inc.股市,Avidity Biosciences, Inc.股票价格,Avidity Biosciences, Inc.股票交易,Avidity Biosciences, Inc.股票购买,Avidity Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction